News & Updates
Filter by Specialty:
Early remdesivir treatment lowers risk of COVID-19 progression
19 Jan 2022
byJairia Dela Cruz
In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.
Early remdesivir treatment lowers risk of COVID-19 progression
19 Jan 2022Anxiety, depressive symptoms in JIA tied to pain, stress
19 Jan 2022
Moderate to severe symptoms of anxiety and depression have been reported in about one-fourth of children with juvenile idiopathic arthritis (JIA), according to a study. Such symptoms are associated with pain and stress, but not with other disease manifestations.
Anxiety, depressive symptoms in JIA tied to pain, stress
19 Jan 2022CATALYST sparks signals favouring namilumab for COVID-19
19 Jan 2022
byAudrey Abella
In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.